目的 探討丹參酮Ⅱ_A磺酸鈉注射液聯(lián)合奧拉西坦治療卒中后認(rèn)知障礙的療效。方法 選擇2019年2月—2020年9月重慶市九龍坡區(qū)人民醫(yī)院收治的83例卒中后認(rèn)知障礙患者作為研究對(duì)象，根據(jù)治療方法將患者分為對(duì)照組（41例）和觀察組（42例）。對(duì)照組患者口服奧拉西坦膠囊，800 mg/次，2次/d，連續(xù)治療2周。觀察組在對(duì)照組基礎(chǔ)上靜脈滴注丹參酮Ⅱ_A磺酸鈉注射液，80 mg加入5%葡萄糖注射液250 mL中，1次/d，連續(xù)治療2周。觀察兩組認(rèn)知功能、記憶功能、生活能力、事件相關(guān)電位P300、炎性因子、氧化應(yīng)激和不良反應(yīng)差異。結(jié)果 兩組治療后MMSE、RBMT評(píng)分、BI指數(shù)、P300波幅、血清總抗氧化能力（T-AOC）水平均較治療前顯著增高，P300潛伏期、血清白細(xì)胞介素-6（IL-6）、C反應(yīng)蛋白（CRP）、丙二醛（MDA）水平較治療前顯著降低（P<0.05）。治療后，觀察組MMSE、RBMT評(píng)分、BI指數(shù)、P300波幅、血清T-AOC水平顯著高于對(duì)照組，P300潛伏期、IL-6、CRP、MDA水平顯著低于對(duì)照組（P<0.05）。結(jié)論 丹參酮Ⅱ_A磺酸鈉注射液聯(lián)合奧拉西坦治療卒中后認(rèn)知障礙可提高認(rèn)知、記憶功能和生活能力，安全性高，優(yōu)于單純奧拉西坦治療。

Objective To investigate the efficacy of TanshinoneⅡ_A Sulfonate Injection combined with oxiracetam in treatment of cognitive impairment after stroke. Methods A total of 83 patients with post-stroke cognitive impairment admitted to Jiulongpo District People's Hospital, Chongqing from February 2019 to September 2020 were selected as the research subjects. According to the treatment methods, the patients were divided into control group (41 cases) and observation group (42 cases). Patients in the control group were po administered with Oxiracetam Capsules, 800 mg/time, twice daily for 2 weeks. Patients in the observation group were iv administered with Sulfotanshinone Sodium Injection on the basis of control group, 80 mg into 5% glucose injection 250 mL, once daily for 2 consecutive weeks. The differences in cognitive function, memory function, life ability, event-related potential P300, inflammatory factors, oxidative stress, and adverse reactions between two groups were observed. Results After treatment, MMSE, RBMT score, BI index, P300 amplitude, serum T-AOC levels were significantly increased in two groups, while P300 latency, serum levels of IL-6, CRP, and MDA were significantly decreased (P < 0.05). After treatment, MMSE, RBMT score, BI index, P300 amplitude and serum T-AOC level in observation group were significantly higher than those in control group, while P300 latency, IL-6, CRP, and MDA levels were significantly lower than those in control group (P < 0.05). Conclusions Sulfotanshinone Sodium Injection combined with oxiracetam in treatment of post-stroke cognitive impairment can improve cognitive, memory function and living ability, with high safety, which is better than olacetam alone.